Cadenza Bio has published a peer-reviewed study in Scientific Reports, a Nature Portfolio journal. This study demonstrates how two of its oral, brain-penetrant ERβ ligands, K102 and K110, promote myelin repair and functional recovery in multiple sclerosis models. Conducted with leading academic collaborators, the study offers strong preclinical evidence supporting the development of new therapies that both modulate inflammation and drive repair in the central nervous system.
Read more here.